Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Dec 24, 2024 12:39pm
108 Views
Post# 36376619

Medical advisor endocrinology

Medical advisor endocrinology

I saw this job posting few months ago filled some 3 months later. Initially I thought although Hybrid why based in Montreal? Anyway he seems to have the experience.."Strong scientific knowledge coupled with robust business acumen, strategic thinking, and advanced knowledge of Canadian drug development environment". Then one has to wonder now that they are going to commercial drugs in Canada why not adding Tesamorelin to the mix. They stopped selling the drug based on a "business decision" (below)most likely lower pricing in Canada and associated costs among others setting up a sale force, administrative costs, self managed centralized inventory(storage and distribution) or a third party distributor...as for logistic I believe Tesamorelin is manufactured locally in Montreal so less costly. Point is cost sharing might make it more feasible to restart the commercialization of the drug despite lower pricing and a small targeted market which was not cost efficient to commercialize alone but it can generate an adds on profit when the company has establish itself as commercial business in Canada!!

Discontinuation report EGRIFTA

Check out this job at Theratechnologies Inc.: 

https://www.linkedin.com/jobs/view/3911887445

 

https://www.linkedin.com/in/christian-caldji-phd-597b7192?utm_source=share&utm_campaign=share_via&utm_content=profile&utm_medium=ios_app

<< Previous
Bullboard Posts
Next >>